Article Abstract

Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?

Authors: Anna W. Chalmers, Shiven B. Patel, Wallace Akerley

Abstract

Stage III non-small cell lung cancer (NSCLC) remains a clinical challenge with only modest improvements in treatment over two decades and a plateau in survival.